Amicus Therapeutics, Inc.
FOLD
Ранг среди акций
#3693
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Цена акции
$14.49
Последняя синхронизация: 2026-04-27
Рыночная капитализация
$4.55B
Изменение (1 день)
0.00%
Изменение (1 год)
71.68%
Страна
US
Торговля Amicus Therapeutics, Inc. (FOLD)
Категория
Healthcare
Коэффициент P/B для Amicus Therapeutics, Inc. (FOLD)
Коэффициент P/B на October 2026 TTM: 16.33
Согласно последним финансовым отчетам и цене акций Amicus Therapeutics, Inc., текущий коэффициент P/B (TTM) составляет 16.33. В конце 2023 он составлял 26.15.
История P/B для Amicus Therapeutics, Inc. с 2003 по 2026
Коэффициент P/B в конце каждого года
| Год | P/B | Изменить |
|---|---|---|
| 2026 (TTM) | 16.33 | 10.47% |
| 2024 | 14.78 | -43.49% |
| 2023 | 26.15 | -8.84% |
| 2022 | 28.68 | 181.23% |
| 2021 | 10.20 | -51.13% |
| 2020 | 20.87 | 324.64% |
| 2019 | 4.92 | -5.30% |
| 2018 | 5.19 | -17.01% |
| 2017 | 6.25 | 237.21% |
| 2016 | 1.85 | -39.50% |
| 2015 | 3.07 | -39.53% |
| 2014 | 5.07 | 92.44% |
| 2013 | 2.63 | 49.32% |
| 2012 | 1.76 | -56.10% |
| 2011 | 4.02 | 100.18% |
| 2010 | 2.01 | 60.55% |
| 2009 | 1.25 | -50.51% |
| 2008 | 2.53 | 83.43% |
| 2007 | 1.38 | -1,105.40% |
| 2006 | -0.14 | -17.07% |
| 2005 | -0.17 | 0.00% |
| 2004 | 0.00 | -100.00% |
| 2003 | -0.84 | 0.00% |
Коэффициент P/B для аналогичных компаний или конкурентов
| Компания | P/B | Разница P/B | Страна |
|---|---|---|---|
| 6.251 | -61.72% |
US
|
|
| 13.2547 | -18.82% |
US
|
|
| 4.208 | -74.23% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -62.14% |
NL
|
